Haemophilia A gene therapy - VIRxSYS
Latest Information Update: 02 Oct 2021
At a glance
- Originator Intronn; Mount Sinai School of Medicine
- Developer VIRxSYS Corporation
- Class Blood coagulation factors; Coagulants
- Mechanism of Action Blood coagulation factor replacements; Factor X stimulants; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Haemophilia A
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Haemophilia-A in USA
- 11 Feb 2011 Preclinical development is ongoing in USA
- 21 Sep 2007 Intronn has been acquired and merged into VIRxSYS Corporation